New hope for tough breast cancer: drug combo trial launches
NCT ID NCT07111832
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a new combination of drugs (SHR-A1811 plus SHR-1316) works better than the current standard treatment for a specific type of advanced breast cancer called PD-L1-positive triple-negative breast cancer. The study will enroll 400 women whose cancer has come back or spread and cannot be removed by surgery. The main goal is to see if the new combo delays cancer growth longer than the standard therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (a targeted drug) plus SHR-1316 (an immunotherapy)
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with a hard-to-treat form of advanced breast cancer, potentially improving how long the cancer stays under control.
- What could go wrong
- This is an early-stage phase 3 trial, so results are not yet known. The new combination may not work better than the current standard treatment, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-L1-POSITIVE LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital，Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China